Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Operating Leases (2023 - 2025)

Axsome Therapeutics (AXSM) has disclosed Operating Leases for 3 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 283.43% to $23.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.2 million through Dec 2025, up 283.43% year-over-year, with the annual reading at $23.2 million for FY2025, 283.43% up from the prior year.
  • Operating Leases hit $23.2 million in Q4 2025 for Axsome Therapeutics, up from $23.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $23.9 million in Q1 2025 to a low of $6.0 million in Q4 2024.
  • Historically, Operating Leases has averaged $13.0 million across 3 years, with a median of $7.5 million in 2023.
  • Biggest five-year swings in Operating Leases: dropped 16.27% in 2024 and later surged 283.43% in 2025.
  • Year by year, Operating Leases stood at $7.0 million in 2023, then decreased by 14.06% to $6.0 million in 2024, then soared by 283.43% to $23.2 million in 2025.
  • Business Quant data shows Operating Leases for AXSM at $23.2 million in Q4 2025, $23.0 million in Q3 2025, and $23.6 million in Q2 2025.